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Open access under CC BY license.were used to determine 3 novel, quantitative, CT-based asthma
phenotypes.
Results: Patients with severe and mild-to-moderate asthma
demonstrated smaller mean right upper lobe apical segmental
bronchus (RB1) lumen volume (LV) in comparison with healthy
control subjects (272.3 mm3 [SD, 112.6 mm3], 259.0 mm3 [SD,
53.3 mm3], 366.4 mm3 [SD, 195.3 mm3], respectively; P 5 .007)
but no difference in RB1 wall volume (WV). Air trapping
measured based on mean lung density expiratory/inspiratory
ratio was greater in patients with severe and mild-to-moderate
asthma compared with that seen in healthy control subjects
(0.861 [SD, 0.05)], 0.866 [SD, 0.07], and 0.830 [SD, 0.06],
respectively; P 5 .04). The fractal dimension of the segmented
airway tree was less in asthmatic patients compared with that
seen in control subjects (P 5 .007). Three novel, quantitative,
CT-based asthma clusters were identified, all of which
demonstrated air trapping. Cluster 1 demonstrates increased
RB1 WV and RB1 LV but decreased RB1 percentage WV. On
the contrary, cluster 3 subjects have the smallest RB1 WV and
LV values but the highest RB1 percentage WV values. There is a
lack of proximal airway remodeling in cluster 2 subjects.
Conclusions: Quantitative CT analysis provides a new
perspective in asthma phenotyping, which might prove useful in
patient selection for novel therapies. (J Allergy Clin Immunol
2014;133:729-38.)
Key words: Asthma, airway remodeling, distal airway, CT, quantita-
tive imaging, phenotypes, cluster analysis, fractal analysis
Asthma remains a major health care burden affecting an
estimated population of 300 million persons worldwide, with an
annual premature fatality of 250,000 persons.1 Approximately
5% to 10% of patients have severe asthma and do not respond
adequately to traditional treatment. These patients have severely
impaired quality of life and impose a disproportionately high
burden on health care resources because of the high risk of
exacerbation, hospitalization, and death.2 There is increasing
recognition that asthma is heterogeneous and comprises
distinct phenotypes.3-5 Statistical techniques, such as factor
and cluster analysis, have been used to dissect asthma heterogene-
ity and identify distinct clinical phenotypes.4 Although
quantitative computed tomography (CT)–based disease pheno-
typing has been used in patients with chronic obstructive pulmo-
nary disease,6,7 this has not yet been fully used in asthmatic
patients. Quantitative CT techniques8-10 now enable assessment
of the proximal airways,9 indirect assessment of the small air-
ways,11 and assessment of the fractal geometry of the tracheo-
bronchial tree.12729
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730 GUPTA ET ALAbbreviations usedATS: American Thoracic SocietyBSA: Body surface areaCT: Computed tomographyDav: Averaged fractal dimensionDe: Most efficient cover fractal dimensionDsc: Slope-corrected fractal dimensionDsce: Slope-corrected most-efficient covering fractal
dimensionFRC: Functional residual capacityHU: Hounsfield unitsICC: Intraclass correlation coefficientLA: Lumen areaLV: Lumen volumeMLD E/I: Mean lung density expiratory/inspiratory ratioPi10: Hypothetical airway with internal perimeter of 10
mmPo20: Hypothetical airways with outer airway perimeter of
20 mmRB1: Right upper lobe apical segmental bronchusROI: Region of interestRV: Residual volumeTLC: Total lung capacityVI: Voxel indexVI2850 E-I: VI2850 change on paired inspiratory and expiratory
CT scanVI2850/2950 E-I: Voxel index change of percent voxels between2950
and 2850 HU on paired inspiratory and expiratory
CT scanWA: Wall areaWV: Wall volumeWe hypothesized that asthma phenotypes, as determined by
using quantitative CT measures of proximal airway remodeling
and air trapping, have distinct clinical and physiologic features.
Our study aims were (1) to compare quantitative CT measures of
proximal airway remodeling and air trapping from volumetric
paired inspiratory and expiratory CT scans between patients with
severe asthma, patients with mild-to-moderate asthma, and
healthy control subjects; (2) to compare the fractal dimension
of segmented airway tree and terminal air space between patients
with severe asthma, patients with mild-to-moderate asthma, and
healthy control subjects; and (3) to use factor and cluster analysis
with quantitative proximal and distal airway CT indices to
generate novel asthma phenotypes and compare their clinical
and physiologic features.METHODS
Detailed methods are available in the Methods section in this article’s
Online Repository at www.jacionline.org.Subjects
Adults with asthma (severe asthma, n5 48; mild-to-moderate asthma, n5
17) and healthy control subjects (n 5 30) were recruited into a single-center
study. Asthma was confirmed by a respiratory physician based on history and
supported by evidence of variable airflow obstruction, airway hyperrespon-
siveness, or both.13 Severe asthma was defined in accordance with American
Thoracic Society (ATS) guidelines.14 Asthmatic patients who did not meet the
ATS severe asthma definition were classified as having mild-to-moderate
asthma. All patients with severe asthma (n 5 48) had previously taken part
in another study.15 Healthy subjects were asymptomatic and had no knownrespiratory illness, with normal spirometric results. All subjects underwent
clinical characterization, including an extensive history, skin prick tests for
common aeroallergens, peripheral blood tests, spirometry, full pulmonary
function tests, methacholine challenge tests, and sputum induction.16
Asthma-related quality of life and asthma control were assessed by using
the Asthma Quality of Life Questionnaire17 and Asthma Control Question-
naire.18 Informed consent was obtained from all subjects, and the study was
approved by the Leicestershire, Northamptonshire, and Rutland Research
Ethics Committee.CT imaging
Volumetric whole-lung scans (Siemens Sensation 16; Siemens, Surrey,
United Kingdom) were acquired at full inspiration and at the end of normal
expiration. Details of CTacquisition and radiation safety (see Table E1 in this
article’s Online Repository at www.jacionline.org) are discussed in the
Methods section in this article’s Online Repository. Fully automated software,
the Volumetric Information Display and Analysis (VIDA) Pulmonary Work-
station, version 2.0 (PW2 software; VIDA Diagnostics, Coralville, Iowa;
http://www.vidadiagnostics.com), was used for quantitative airwaymorphom-
etry, lung densitometry (see Fig E1 in this article’s Online Repository at www.
jacionline.org) and calibrated by using density measures of air, blood, and
electron density rods (see Fig E2 in this article’s Online Repository at www.
jacionline.org) and fractal dimension (see Figs E3 and E4 in this article’s On-
line Repository at www.jacionline.org) analysis. The repeatability (see Fig E5
in this article’s Online Repository at www.jacionline.org) and accuracy (see
Fig E6 in this article’s Online Repository at www.jacionline.org) of airway
morphometry were assessed. Ninety-five percent CIs of mean lung density
expiratory/inspiratory ratio (MLD E/I) among healthy control subjects was
considered the normal range for CT air trapping. CT air trapping in asthmatic
patients was graded based on MLD E/I values: (1) severe, greater than the
upper limit of the 99.5% CI of the MLD E/I in healthy control subjects; (2)
moderate, greater than the upper limit of the 98%CI of theMLDE/I in healthy
control subjects; and (3)mild, greater than the upper limit of the 95%CI of the
MLD E/I in healthy control subjects.Statistical analysis
Statistical analysis was performed with GraphPad Prism 5.00 (GraphPad
Software, San Diego, Calif) and SPSS (SPSS, Chicago, Ill) software.
Parametric data were expressed as means (SDs), and nonparametric data
were described as medians (interquartile ranges). Log-transformed data are
presented as geometric means (95% CIs). The x2 and Fisher exact tests were
used to compare ratios. One-way ANOVA with the Tukey correction (para-
metric data) and the Kruskal-Wallis test with the Dunn intergroup comparison
(nonparametric data) were used to compare multiple groups. The Pearson cor-
relation coefficient was used to determine airway structure and function rela-
tionships. Unsupervised multivariate modeling with principal component and
cluster analysis was performed to extract factors that best describe the under-
lying relationship among the quantitative CT variables and determine cluster
membership of all asthmatic patients. A 2-way random-effects model with ab-
solute agreement intraclass correlation coefficients (ICCs) was used to assess
single-measure reliability for the (1) lumen area (LA), wall area (WA), and
length measurements of Leicester Airway Phantom tubes 4 to 9 by a single
observer 2months apart and (2) LA/WA and lengthmeasurements of Leicester
Airway Phantom tubes 4 to 9 by using a steromicroscope and Vernier caliper,
respectively, compared with PW2 software measurements. A P value of less
than .05 was taken as statistically significant.RESULTS
Baseline demographics and clinical characteristics of patients
with severe (n 5 48) or mild-to-moderate (n 5 17) asthma and
healthy control subjects (n5 30) are shown in Table I. Among the
3 groups, no significant differences were found in age, sex, body
surface area (BSA), and smoking status.
TABLE I. Clinical characteristics of asthmatic patients and healthy subjects
Patients with severe
asthma (n 5 48)
Patients with mild-to-moderate
asthma (n 5 17)
Healthy control subjects
(n 5 30)
Significance
(P value)
Age (y) 50.7 (9.9) 53.0 (16.3) 56.9 (12.5) .09
Sex (M/F) 24/24 10/7 16/14 .8
BMI (kg/m2) 28.8 (6.4) 28.3 (5.2) 28.3 (5.2) .9
BSA (m2) 1.9 (0.2) 1.9 (0.2) 1.9 (0.2) 1.0
Disease duration (y) 26.8 (16.3) 33.2 (5.7) x .2
Smoking status (%)
Never 77 59 52 .2
Exsmoker 21 35 41
Current smoker 2 6 7
Smoking history >10 pack years (%) 6 12 13 .3
Atopy (%) 67 82 18 <.0005
Aspergillus species sensitization (%) 23 36 7 .08
Severe exacerbations/y 3.0 (1.0-5.3) 1.0 (0-2.5) x .007
Modified ACQ score (symptoms only) 2.6 (1.3) 1.8 (1.4) x .04
AQLQ score 8.3 (25.1) 5.2 (1.4) x .6
Prebronchodilator FEV1 (% predicted) 69.2 (20.1) 79.0 (23.4) 110.9 (15.9) <.0005§
Prebronchodilator FEV1/FVC ratio (%) 67.9 (12.1) 69.7 (10.3) 78.3 (5.6) <.0005§
Postbronchodilator FEV1 (% predicted) 74.4 (19.2) 81.3 (22.7) 112.7 (17.3) <.0005§
Postbronchodilator FEV1/FVC ratio (%) 69.9 (11.9) 69.8 (10.4) 79.9 (6.0) <.0005§
Bronchodilator response (%) 9.6 (14.7) 3.5 (6.8) 1.6 (3.5) .0007
Midexpiratory flow (L/s) 2.0 (1.1) 1.8 (0.9) 3.2 (0.9) <.0005§
Vital capacity (L) 3.7 (1.1) 4.0 (0.8) 4.2 (0.9) .2
Functional residual capacity (L) 3.0 (1.2) 2.9 (0.9) 3.1 (0.9) .9
RV (L) 2.1 (0.9) 2.0 (0.9) 2.2 (0.8) .8
TLC (L) 5.8 (1.7) 5.9 (1.4) 6.3 (1.2) .6
RV/TLC (%) 35.7 (12.3) 31.2 (9.4) 33.6 (15.3) .7
Methacholine PC20 (mg/mL)* 2.0 (0.7-6.0) 2.4 (0.8-7.3) 24.4 (17.6-33.7) <.0005§
FENO (ppb)* 36.1 (27.7-47.0) 26.4 (18.6-37.5) 27.2 (21.1-34.7) .2
Total IgE (kU/L)* 179.0 (128.7-248.9) 137.0 (68.5-273.8) 25.5 (15.8-41.0) <.0005§
Inhaled CS (%) 100 82 x .02
Inhaled CS dose, BDP (mg/24 h) 2000 (1600-2000) 1000 (600-2000) x .004
LABA (%) 94 71 x .03
Oral CS (%) 68 0 x <.0005
Montelukast (%) 32 0 x .007
Theophylline (%) 40 24 x .3
Sputum eosinophils (%)* 4.3 (2.5-7.5) 2.0 (0.8-4.8) 0.7 (0.4-.1) <.0005
Sputum total neutrophils 3 106 (cells/g) 2.8 (7.0) 4.0 (5.2) 2.9 (3.9) .9
Data are expressed as means (SDs). The Pearson x2 and Fisher exact test were used to compare ratios. Beclomethasone dipropionate equivalents are as follows: fluticasone, 2:1;
budesonide, 1.25:1; mometasone, 1.25:1; QVAR, 2:1; and ciclesonide, 2.5:1.
ACS, Asthma Control Score; BDP, beclomethasone dipropionate; BMI, body mass index; CS, corticosteroid; FENO, fraction of exhaled nitric oxide; FVC, forced vital capacity;
LABA, long-acting b2-agonist.
*Geometric mean (95% CI).
Median (interquartile range).
Intergroup comparisons
For parametric data, 1-way ANOVAwith the Tukey test to compare all pairs of columns: P < .05, patients with severe asthma versus healthy control subjects; §P < .05, patients
with mild-to-moderate asthma versus healthy control subjects; and kP < .05, patients with severe asthma versus patients with mild-to-moderate asthma.
For nonparametric data, Kruskal-Wallis test with the Dunn multiple comparison test to compare all pairs of columns: P < .05, patients with severe asthma versus healthy control
subjects; §P < .05, patients with mild-to-moderate asthma versus healthy control subjects; and kP < .05, patients with severe asthma versus patients with mild-to-moderate asthma,
Mann-Whitney U test.
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On inspiratory CT scans, mean right upper lobe apical
segmental bronchus (RB1) percentage wall volume (WV) was
significantly higher in the groups with severe asthma and mild-to-
moderate asthma compared with the healthy control subjects
(62.4% [SD, 3.6%], 61.4% [SD, 2.9%], and 58.5% [SD, 3.6%],
respectively; P < .0005). Patients with severe and mild-to-
moderate asthma had smaller mean RB1 lumen volume (LV) in
comparison with that seen in healthy control subjects (272.3
mm3 [SD, 112.6 mm3], 259.0 mm3 [SD, 53.3 mm3], and 366.4
mm3 [SD, 195.3 mm3], respectively; P 5 .007; see Fig E7
in this article’s Online Repository at www.jacionline.org).No significant difference in RB1 dimension was found among
the 2 asthma groups (Table II). Assessment of 3 other segmental
bronchi (RB10, LB112, and LB10) on inspiratory CT scans
revealed results similar to those for RB1. Mean (SD) LVor LA/
BSA values of all the additional segmental bronchi assessed
were significantly less in asthmatic patients compared with those
seen in healthy control subjects (see Table E2 in this article’s
Online Repository at www.jacionline.org). RB10 and LB10
(but not LB112) percentage WV was significantly greater in
asthmatic patients compared with that seen in healthy control
subjects (see Table E2). RB1 lumen and wall dimensions showed
good correlation with average lumen and wall dimensions of
TABLE II. RB1 dimensions of asthmatic patients and healthy subjects
Patients with severe
asthma (n 5 48)
Patients with mild-to-moderate
asthma (n 5 17)
Healthy control subjects
(n 5 30)
Significance
(P value)
Inspiratory
Wall area/BSA (mm2/m2) 18.2 (5.5) 18.5 (3.7) 18.7 (5.2) .9
Lumen area/BSA (mm2/m2) 11.3 (4.4) 11.7 (3.0) 13.7 (5.2) .08
Total area/BSA (mm2/m2) 29.5 (9.7) 30.2 (6.4) 32.3 (10.3) .4
Wall area (mm2) 34.8 (10.6) 35.6 (8.0) 36.1 (10.7) .8
Lumen area (mm2) 21.6 (8.4) 22.6 (6.5) 26 (10.3) .06
Total area (mm2) 56.4 (18.7) 58.2 (14.2) 62.6 (20.8) .4
Length (mm) 12.8 (2.7) 11.8 (2.4) 13.7 (4.4) .2
Wall volume (mm3) 437.6 (144.0) 412.9 (88.5) 496.3 (222.1) .2
LV (mm3) 272.3 (112.6) 259.0 (53.3) 366.4 (195.3) .007*
Total volume (mm3) 709.9 (252.4) 672.0 (134.9) 862.8 (414.6) .05
Wall volume (%) 62.4 (3.6) 61.4 (2.9) 58.5 (3.6) <.0005*
Data are expressed as means (SDs).
BSA, Body surface area.
Intergroup comparisons
One-way ANOVA with the Tukey test to compare all pairs of columns: *P < .05, patients with severe asthma versus healthy control subjects; P < .05, patients with mild-to-
moderate asthma versus healthy control subjects; and P < .05, patients with severe asthma versus patients with mild-to-moderate asthma.
TABLE III. Densitometric indices in asthmatic patients and healthy subjects
Patients with severe
asthma (n 5 48)
Patients with mild-to-moderate
asthma (n 5 17)
Healthy control subjects
(n 5 30)
Significance
(P value)
Inspiratory
Lung volume (L) 5.15 (1.5) 5.02 (1.4) 5.49 (1.2) .4
Mean lung density (HU) 2830.9 (40.8) 2831.5 (42.7) 2837.8 (26.2) .7
VI 2950 (%) 11.2 (5.8) 11.9 (7.6) 10.1 (5.5) .6
Percentile 15 (HU) 2932.8 (30.4) 2934.3 (28.2) 2930.1 (22.3) .9
VI 2850 (%) 59.1 (15.5) 59.9 (17.2) 61.8 (13.1) .8
Expiratory
Lung volume (L) 2.9 (1.0) 2.9 (1.1) 2.8 (0.8) .9
Mean lung density (HU) 2713.3 (53.2) 2719.5 (63.0) 2695.6 (55.0) .3
Air-trapping indices
Expiratory VI 2850 (%) 19.7 (11.5) 22.0 (18.0) 16.2 (11.5) .3
MLD E/I 0.861 (0.05) 0.866 (0.07) 0.830 (0.06) .04
VI2850/2950 E-I (%) 230.4 (9.7) 229.1 (18.8) 236.9 (10.2) .04
VI2850 E-I (%) 239.1 (11.5) 237.8 (20.1) 245.6 (12.0) .08
Data are expressed as means (SDs).
Intergroup comparisons
One-way ANOVAwith the Tukey test was used to compare all pairs of columns. All densitometric indices were standardized for extrathoracic air, blood, and 3 electron density rods.
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respectively (Pearson correlation coefficient, r 5 0.7; P < .001).
Hypothetical airway with an internal perimeter of 10 mm (Pi10)
WA and hypothetical airway with an outer airway perimeter of
20 mm (Po20) percentage WA values were greater in patients
with severe asthma compared with those seen in healthy control
subjects (see Table E3 in this article’s Online Repository at
www.jacionline.org).Air trapping
CT-assessed lung volumes on inspiratory and expiratory
scans were similar among the 3 groups (Table III). Air-
trapping indices, MLD E/I values, and voxel index [VI]
2850 changes on paired inspiratory and expiratory CT scans
(VI-850 E-I) were significantly greater in asthmatic patients
compared with those in healthy control subjects (Table III).
The upper limits of the 99.5%, 98%, and 95% CIs of MLD
E/I values in healthy control subjects were 0.862, 0.853, and
0.849, respectively. On assessment of all study subjects, therewas no significant difference between expiratory CT lung
volume and functional residual capacity (FRC) calculated on
full lung function tests (mean, 2.9 L [SD, 0.9 L] vs 3.0 L
[SD, 1.0 L]; P 5 .2). Inspiratory CT lung volume was less
than total lung capacity (TLC), as assessed by using full
lung function tests (mean, 5.2 L [SD, 1.4 L] vs 6.0 L
[SD, 1.5 L]; P < .0005).Fractal dimension
On inspiratory CT, the average fractal dimension (Dav) of the
segmented airway tree was significantly less in asthmatic patients
compared with that seen in control subjects, indicating decreased
complexity of the branching airway tree in asthmatic patients (see
Table E4 and Fig E8 in this article’s Online Repository at www.
jacionline.org). The fractal dimension of the low attenuation clus-
ter at a threshold of 2950 Hounsfield units (HU) on inspiratory
scans and the fractal dimension of the low attenuation cluster at
a threshold of 2850 HU on expiratory scans were not different
across the 3 groups (see Table E4).
TABLE IV. Univariate analysis of the relationship between clinical indices and proximal airway dimensions on inspiratory scans or
CT air trapping (n 5 65)
Post-BD FEV1
(% predicted)
Post-BD
FEV1/FVC
ratio (%)
Midexpiratory
flow (L/s) RV/TLC (%)
Disease
duration (y)
Sputum total
neutrophils 3 106
(cells/g)
Log sputum
eosinophil
count ACQ
Proximal airway dimensions
(inspiratory scan)
RB1 LA/BSA (mm2/m2) 20.10 20.06 20.02 0.30 20.02 0.13 0.08 20.17
RB1 WA/BSA (mm2/m2) 20.07 20.04 20.05 0.20 0.08 0.10 0.08 20.13
RB1 TA/BSA (mm2/m2) 20.09 20.06 20.04 0.25 0.03 0.11 0.08 20.15
RB1 LV (mm3) 20.01 20.06 0.08 0.21 20.04 0.10 20.03 20.18
RB1 wall volume (mm3) 0.05 20.05 0.08 0.11 0.05 0.06 20.04 20.16
RB1 total volume (mm3) 0.03 20.06 0.08 0.15 0.01 0.08 20.04 20.17
RB1 % WV 0.08 0.05 20.02 20.35* 0.19 20.11 20.06 0.19
Pi10 WA (mm2) 20.21 20.27* 20.34* 0.21 20.07 0.04 20.10 0.17
Po20 % WA 20.11 20.10 20.14 0.02 0.05 0.03 20.22 0.19
Air-trapping indices
Expiratory mean lung density
(HU)
0.45 0.64 0.47 20.63 20.35* 0.03 20.38* 20.10
Expiratory VI 2850 (%) 20.48 20.68 20.48 0.64 0.27 0.10 0.23 0.15
MLD E/I 20.40 20.48 20.60 0.46 0.29* 0.17 0.02 0.23
VI2850/2950 E-I (%) 20.30* 20.32* 20.41 0.34* 0.03 0.34* 20.23 0.30*
VI2850 E-I (%) 20.22 20.15 20.33* 0.25 20.03 0.37* 20.27 0.28*
Data are expressed as the Pearson correlation coefficient: *P < .05 and P < .001.
ACQ, Asthma Control Questionnaire; BD, bronchodilator; FVC, forced vital capacity; TA, total area.
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relationships
Good correlation was observed between air-trapping indices
and the hypothetical airway measurements Pi10 WA or Po20
percentage WV (see Table E5 in this article’s Online Repository
at www.jacionline.org) but not between air-trapping indices and
RB1 dimensions. Pi10 WAvalues inversely correlated with post-
bronchodilator FEV1/forced vital capacity ratios (r520.27, P <
.05) and midexpiratory flow rates (r 5 20.34, P < .05).
A significant inverse correlationwas also found betweenRB1 per-
centage WV and percentage residual volume (RV)/TLC (r 5
20.35, P < .05, Table IV). MLD E/I values positively correlated
with RV/TLC ratios (r5 0.46, P <.001) and negatively correlated
with postbronchodilator FEV1 percent predicted values (r 5
20.4, P < .001), postbronchodilator FEV1/forced vital capacity
ratios (r 5 20.48, P < .001), and midexpiratory flow rates (r 5
20.6, P < .001). Other CT indices of air trapping also demon-
strated similar correlation with lung function test results (Table
IV). Disease duration, Asthma Control Questionnaire scores,
and sputum eosinophil and neutrophil counts also showed corre-
lations with CT air-trapping indices (Table IV).Unbiased CT phenotyping using factor and cluster
analysis
The CT parameters were best described by 3 factors (see
Table E6 in this article’s Online Repository at www.jacionline.
org). These factors were used in a cluster analysis, which
identified 3 clusters. Clinical and quantitative CT characteris-
tics of 3 asthma phenotypes determined by using cluster
analysis are shown in Tables V and VI, respectively. All
3 asthma clusters demonstrate air trapping, suggesting the
presence of small-airway disease. Clusters 1 and 3 demonstrate
severe CT air trapping compared with the moderate CT air
trapping seen in cluster 2. The normal range of expiratoryVI 2850 calculated from the 95% CI of the variable in healthy
control subjects was 12.1% to 20.3%. The proportion of
subjects with an expiratory VI 2850 value of greater than
20.3% was higher in clusters 1 and 3 compared with that
seen in cluster 2. Asthmatic patients in cluster 1, in addition
to severe air trapping, had increased RB1 WV and LV but
decreased RB1 percentage WV values. On the contrary, cluster
3 subjects, in addition to severe air trapping, had the smallest
RB1 WV and LV values but highest RB1 percentage WV
values in comparison with the other clusters (Fig 1). The
fractal dimension of the segmented airway tree was highest
in cluster 1. CT phenotyping performed by using average
dimensions of 4 (RB1, RB10, LB112, and LB10; n 5 44)
segmental bronchi also identified 3 clusters with similar
quantitative CT indices (cluster 1: LA/BSA of 14.3 mm2/m2
[1.5 mm2/m2] and WA/BSA of 21.0 mm2/m2 [1.3 mm2/m2];
cluster 2: LA/BSA of 13.1 mm2/m2 [0.7 mm2/m2] and
WA/BSA of 19.6 mm2/m2 [0.8 mm2/m2]; and cluster 3:
LA/BSA of 12.4 mm2/m2 [0.6 mm2/m2] and WA/BSA of
18.8 mm2/m2 [0.6 mm2/m2]).
No significant differences were found among the 3 clusters
with regard to age, sex distribution, disease duration, smoking
status, symptom score, severe exacerbation frequency, atopy,
Aspergillus species sensitization, and sputum eosinophilic or
neutrophilic inflammation. Subjects in clusters 1 and 3 were
more often treated with long-acting b2-agonists compared with
those in cluster 2. In clusters 1 and 3 the proportion of patients
with severe asthma was greater. Subjects in clusters 1 and 3 had
significantly higher RV/TLC percentages and lower prebroncho-
dilator and postbronchodilator FEV1 percent predicted values
compared with those in cluster 2. Subjects in cluster 3 had
increased bodymass index comparedwith the other groups. Bron-
chodilator responsewas significantly lower in cluster 2 subjects in
comparison with those in other clusters. Clinical characteristics
and quantitative CT indices of asthmatic patients in 3 asthma
TABLE V. Clinical characteristics of asthma phenotypes
Asthma cluster 1: Severe
air trapping, bronchial wall
thickening, and bronchial
lumen dilatation (n 5 11)
Asthma cluster 2:
Moderate air trapping
(n 5 34)
Asthma cluster 3: Severe
air trapping and bronchial
lumen narrowing (n 5 17)
Significance
(P value)
Age (y) 51.9 (9.6) 49.3 (13.1) 54.7 (10.4) .3
Sex (M/F) 4:7 17:17 9:8 .7
BMI (kg/m2) 25.0 (3.4) 28.3 (5.5) 31.5 (7.3) .02§
BSA (m2) 1.9 (0.2) 1.9 (0.2) 2.0 (0.3) .3
Patients with severe asthma (%) 81.8 58.8 94.1 .02
Disease duration (y) 26.3 (16.1) 26.4 (16.1) 27.2 (17.5) 1.0
Smoking status (%)
Never 60 74 82 .6
Exsmoker 40 23 18
Current smoker 0 3 0
Smoking history >10 pack years (%) 8 3 13 .5
Atopy (%) 73 69 69 1.0
Aspergillus species sensitization (%) 36 17 29 .4
Severe exacerbations/y 2.5 (1-4.25) 1.5 (0-5.0) 2 (1.0-6.5) .6
Modified ACQ score (symptoms only) 2.1 (0.9) 2.0 (1.5) 2.8 (1.3) .1
AQLQ score 4.9 (1.0) 5.0 (1.4) 4.1 (1.1) .09
Prebronchodilator FEV1 (% predicted) 58.0 (17.3) 80.7 (19.9) 64.0 (19.6) .001k
Prebronchodilator FEV1/FVC ratio (%) 64.8 (12.9) 71.1 (9.7) 67.0 (13.5) .2
Postbronchodilator FEV1 (% predicted) 63.8 (17.7) 83.8 (20.0) 70.6 (16.6) .005k
Postbronchodilator FEV1/FVC ratio (%) 67.0 (13.2) 72.8 (10.4) 67.2 (10.7) .2
Bronchodilator response (%) 11.1 (11.8) 4.4 (7.2) 13.9 (20.8) .04k
Midexpiratory flow (L/s) 2.0 (1.4) 2.1 (0.9) 1.9 (1.0) .8
Vital capacity (L) 3.5 (1.0) 4.0 (1.0) 3.6 (1.1) .4
Functional residual capacity (L) 3.6 (1.2) 2.7 (0.8) 2.7 (1.1) .06
RV (L) 2.7 (0.9) 1.7 (0.7) 2.1 (1.0) .02
TLC (L) 6.2 (1.4) 5.7 (1.4) 5.8 (1.9) .8
RV/TLC (%) 43.5 (11.2) 29.1 (6.3) 35.5 (10.6) .001
Methacholine PC20 (mg/mL)* 1.5 (0.1-16.4) 3.7 (1.2-11.5) 0.7 (0.07-5.6) .2
FENO (ppb)* 37.5 (20.0-70.2) 30.5 (22.6-41.3) 38.8 (24.5-61.4) .6
Total IgE (kU/L)* 227.2 (81.3-634.9) 139.2 (97.3-199.1) 217.9 (110.0-432.4) .3
Inhaled CS (%) 100 91 100 .3
Inhaled CS dose BDP (mg/24 h) 2000 (1450-2000) 2000 (1000-2000) 2000 (1500-2000) .2
LABA (%) 100 77 100 .03
Oral CS (%) 60 41 53 .5
Montelukast (%) 10 24 29 .5
Theophylline (%) 40 29 35 .8
Sputum eosinophils (%)* 2.8 (0.9-8.4) 3.3 (1.6-6.7) 5.7 (1.5-20.6) .6
Sputum total neutrophils 3 106 (cells/g) 2.0 (1.8) 2.4 (3.6) 2.4 (2.1) .9
Data are expressed as means (SDs). Pearson x2 and Fisher exact tests were used to compare ratios. Beclomethasone dipropionate equivalents are as follows: fluticasone, 2:1;
budesonide, 1.25:1; mometasone, 1.25:1; QVAR, 2:1; and ciclesonide, 2.5:1.
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BDP, beclomethasone dipropionate; BMI, body mass index; CS, corticosteroid; FENO, fraction
of exhaled nitric oxide; FVC, forced vital capacity; LABA, long-acting b2-agonist.
*Geometric mean (95% CI).
Median (interquartile range).
Intergroup comparisons
For parametric data, 1-way ANOVA with the Tukey test to compare all pairs of columns: P < .05, asthma cluster 1 versus asthma cluster 2; §P < .05, asthma cluster 1 versus
asthma cluster 3; and kP < .05, asthma cluster 2 versus asthma cluster 3.
For nonparametric data, Kruskal-Wallis test with the Dunn multiple comparison test to compare all pairs of columns: P < .05, asthma cluster 1 versus asthma cluster 2; §P < .05,
asthma cluster 1 versus asthma cluster 3; and kP < .05, asthma cluster 2 versus asthma cluster 3.
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exclusion of subjects with a smoking history of greater than 10
pack years (see Table E7 in this article’s Online Repository at
www.jacionline.org).
DISCUSSION
We found that in asthmatic patients there was airway remodel-
ing with reduced luminal volume and increased percentage WV
compared with that seen in healthy subjects, irrespective of
disease severity. This increase in percentage WV was largely
driven by the reduction in luminal volume with no significantdifference inWVbetween asthma and health, thus suggesting that
airway remodeling reflects complex changes in the airway
geometry rather than simply an increase in WV. Air trapping
was increased in asthmatic patients compared with that seen in
healthy subjects. The fractal dimension of the segmented airway
tree was significantly less in asthmatic patients compared with
that in healthy subjects on an inspiratory scan, indicating a loss of
complexity and decrease in the space-filling ability of these
airways. Using CT indices of proximal airway remodeling and air
trapping, we identified 3 novel asthma phenotypes with distinct
clinical and radiologic features.
TABLE VI. Quantitative CT indices of asthma phenotypes
Asthma cluster 1: Severe air
trapping, bronchial wall thickening,
and bronchial lumen dilatation
(n 5 11)
Asthma cluster 2:
Moderate air trapping
(n 5 34)
Asthma cluster 3: Severe
air trapping and bronchial
lumen narrowing (n 5 17)
Significance
(P value)
Proximal airway dimensions
(inspiratory)
RB1 % wall volume 58.1 (2.7) 62.0 (2.6) 64.8 (3.0) <.005*
RB1 wall area/BSA (mm2/m2) 25.0 (3.3) 19.2 (2.5) 12.3 (3.2) <.005*
RB1 lumen area/BSA (mm2/m2) 18.0 (2.0) 11.7 (1.7) 6.7 (1.7) <.005*
RB1 total area/BSA (mm2/m2) 42.9 (4.9) 30.9 (3.8) 18.9 (4.8) <.005*
RB1 length (mm) 11.6 (2.6) 12.5 (2.5) 13.5 (2.8) .2
RB1 wall volume (mm3) 540.5 (92.8) 453.1 (120.4) 324.2 (102.9) <.005
RB1 wall volume (% greater than
upper 95% CI of healthy control
subjects)
27 15 6 .3
RB1 LV (mm3) 392.2 (78.6) 278.0 (78.0) 176.1 (54.0) <.005*
RB1 LV (% less than lower 95% CI of
healthy control subjects)
9 65 94 <.005
RB1 total volume (mm3) 932.7 (163.3) 731.2 (194.8) 500.3 (154.4) <.005*
Pi10 wall area (mm2) 16.9 (1.9) 16.2 (1.7) 16.2 (1.4) .5
Po20 % wall area 64.7 (2.5) 64.8 (2.3) 65.5 (2.5) .6
Air trapping
Expiratory VI 2850 (%) 23.7 (16.0) 17.2 (11.9) 24.8 (13.9) .1
Expiratory VI 2850 (% greater than
upper 95% CI of healthy control
subjects)
64 29 59 .045
VI2850/2950 E-I (%) 228.6 (12.8) 231.7 (13.5) 227.6 (11.4) .5
VI2850 E-I (%) 235.9 (14.2) 239.9 (15.5) 238.3 (12.2) .7
MLD E/I 0.876 (0.06) 0.857 (0.06) 0.864 (0.05) .6
MLD E/I (% greater than upper 95%
CI of healthy control subjects)
73 53 65 .5
Fractal dimension
Inspiratory Dav 1.712 (0.04) 1.686 (0.04) 1.671 (0.04) .04
Inspiratory Dav (% less than lower
95% CI of healthy control subjects)
46 65 77 .2
Expiratory LAC-D 2850 1.838 (0.09) 1.814 (0.1) 1.794 (0.05) .4
Data are expressed as means (SDs).
LAC-D 2850, Fractal dimension of low attenuation cluster at a threshold of 2850 HU.
Intergroup comparisons
One-way ANOVAwith the Tukey test to compare all pairs of columns: *P < .05, asthma cluster 1 versus asthma cluster 2; P < .05, asthma cluster 1 versus asthma cluster 3; and
P < .05, asthma cluster 2 versus asthma cluster 3.
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of asthma,9,19 is heterogeneous, with variable changes in wall and
lumen dimensions reported by several authors.8-10,20 Our results
demonstrate lumen narrowing as a predominant feature of prox-
imal airway remodeling in asthmatic patients, which is in keeping
with our previous observations10 and those obtained by using
optical coherence tomography.21 It is difficult to attribute the
airway narrowing we observed in asthmatic patients to increased
smooth muscle tone because all subjects were scanned after
bronchodilator use. However, in some subjects airway smooth
muscle tone might be partly refractory. We are confident that
the changes observed in RB1 are generally reflective of changes
throughout the airway tree as in spite of the heterogeneity of
airway remodeling; RB1 has been shown to emulate changes in
other proximal airways.9,10,22 Likewise, in our study the differ-
ences in RB1 dimensions between the asthmatic and healthy
groups were reflected in airway remodeling patterns of 3 other
proximal airways and 2 hypothetical airways, confirming that
RB1 is a good surrogate for proximal airway remodeling.
Air-trapping indices were derived from paired inspiratory
and expiratory scans after calibration by using density measuresof air, blood, and electron density rods. X-ray tube aging and
replacement might introduce errors in densitometric measures23
despite standard CT scanner quality assurance procedures.24
Therefore densitometric calibration is critical, and our study is
the first to apply this for assessment of air trapping in asthmatic
patients. The air trapping indices, MLD E/I and VI-850 E-I,
were significantly greater in asthmatic patients compared with
those seen in healthy subjects, which is in keeping with observa-
tions by other authors.25,26 In our study CT air trapping indices
correlated with 2 hypothetical airways but not with any other
proximal airway dimensions. Univariate analysis of CT air-
trapping indices, in contrast to proximal airway remodeling,
showed a much stronger correlation with lung function and dis-
ease duration. Previous studies8-10,25,26 have also demonstrated
correlations between CT and clinical indices, thus highlighting
the importance of structure-function relationships in asthmatic
patients.
For the first time, we have used an unbiased method to
determine 3 distinct asthma phenotypes based on CT measures
of proximal airway remodeling and air trapping. Previously, we
did not find any differences in proximal airway remodeling in
FIG 1. Proximal airway remodeling in asthma phenotypes. Pictures of segmented airway tree and RB1 CT
cross-section (insets) of asthmatic patients from cluster 1 (A), cluster 2 (B), and cluster 3 (C) are shown.
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rent analysis. Both CT and physiologic measures demonstrate
more severe air trapping in clusters 1 and 3 compared with cluster
2. Clusters 1 and 3 demonstrate poorer lung function compared
with cluster 2. Moreover, lack of proximal airway remodeling
in cluster 2 implies that this phenotype represents asthmatic pa-
tients with mild disease. Similarly, others report9,27 no significant
differences in airway dimensions between the patients with mild-
to-moderate asthma and healthy subjects. Wagner et al28 have
shown a 7-fold increase in distal airway resistance in asthmatic
patients with mild disease and normal spirometric results
compared with healthy subjects. Taken together, these findings
perhaps suggest that small-airway involvement in asthmatic pa-
tients precedes proximal airway remodeling. Cluster 1 subjects
have significantly increased RB1 lumen and wall dimensions,
whereas in contrast, cluster 3 subjects demonstrate luminal
narrowing. Whether this represents pathologic dilatation of the
airways in cluster 1 patients needs to be determined. The bronchi-
ectasis phenotype of asthma has been described previously,29-31
which correlates negatively with FEV1
32 and positively with air
trapping.33 Similar to cluster 3 subjects, numerous CT studies
have also demonstrated an increased percentage WA or percent-
age wall thickness in patients with severe asthma compared
with healthy subjects.8-10,22,25,34 The phenotypes identified in
our study do not align with clinical asthma phenotypes previously
identified by our group10 and with traditional methods of asthma
classification. The CT-derived phenotypes most likely represent a
different aspect of asthma based on airway structural changes that
are difficult to identify purely on the basis of demographic pro-
files, inflammatory indices, and lung function test results.
Whether the CT-derived phenotypes we describe here represent
distinct asthma endotypes5 with discrete pathogenic pathways
or indicate a progressive disease captured at different stages of
airway remodeling is uncertain and warrants further study.
Our finding of a decreased fractal dimension of the segmented
airway tree in asthmatic patients compared with healthy subjects
is consistent with similar analyses of the bronchial tree,35 peak
expiratory flow time series,36 and fluctuation in daily fraction ofexhaled nitric oxide levels37 in asthmatic patients. To determine
the fractal dimension, we used the digital picture of the segmented
airway tree obtained from CT scans using PW2 software, in
contrast to the study by Boser et al,35 in which a digital picture
of a silicone rubber cast of airways from postmortem subjects
was used. Despite these differences in the method used by Boser
et al and our group, the fractal dimension values obtained were
similar. Reduced fractal dimension and hence the complexity of
the airway tree might be fundamental in understanding the disor-
dered physiology and exacerbation events38 associated with
asthma. Fractal dimension of low attenuation clusters at a
threshold of 2950 HU on inspiratory scans can help detect early
emphysema.39 In keeping with previous studies,29,30,40 there was
no evidence of emphysema in asthmatic patients because both VI
2950 values and fractal dimension of low attenuation clusters at a
threshold of 2950 HU were not significantly different compared
with values seen in healthy subjects.
Our study has a number of potential limitations. Inspiratory and
expiratory CT scans obtained were not spirometrically gated. We
are confident that the differences observed in airway dimensions
between asthmatic patients and healthy subjects in our study are
not due to differences in lung volume because all subjects
practiced breath holding before CT scans and no significant
differences were found in inspiratory or expiratory lung volumes
between groups. Expiratory CT–assessed lung volume was not
significantly different from physiologically assessed FRC. Inspi-
ratory CT–assessed lung volume, although lower than physiolog-
ically assessed TLC, was similar in healthy subjects and patients
with mild-to-moderate or severe asthma. Studies have shown that
it is unlikely that spirometric gating will further improve
quantitative CT repeatability.41 Moreover, animal studies have
demonstrated that airways do not distend isotropically with the
lung, and after elimination of bronchial tone, airway lumen rea-
ches a plateau at low transpulmonary pressurewith trivial changes
in LA on further increase of transpulmonary pressure.42,43 All 48
patients with severe asthma in our study had previously taken part
in another study.15 This group fulfilled the ATS refractory asthma
definition,14 had 2 or more severe exacerbations in the last year,
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years but not necessarily at the point of screening or randomiza-
tion. These criteria were fulfilled by one third of the unselected
severe asthma population assessed at our center. Therefore
patients with severe asthma in our study might not be fully
representative of the unselected population and would have a
higher number of patients with frequent exacerbations and
eosinophilic inflammation but are representative of at least a large
proportion of the population with severe asthma. Moreover,
unselected patients with mild-to-moderate asthma were also
included in this study. Another potential criticism of our study
is that the asthma clusters presented here were determined based
on proximal airway dimensions of a single airway together with
air-trapping indices and fractal dimensions. In keeping with
previous studies,9,10,22 we found a close association between
RB1 and other airways, and CT-derived clusters in the subset of
subjects with available data using the average dimension of 4
segmental airways identified 3 clusters with similar quantitative
CT indices to the clusters identified using RB1 dimensions alone.
This suggests that despite heterogeneity, remodeling in RB1
reflects changes in other proximal airways. The number of
healthy control subjects in this study is small, and therefore the
normal ranges of quantitative CT indices generated might not
be representative of the unselected healthy population. Larger
data sets that include sufficient numbers of subjects to study
the effects of age, sex, and ethnicity are required to generate
population normal ranges.
Our study has further extended the tools to investigate asthma
heterogeneity44 and for the first time used CT indices of proximal
airway remodeling and air trapping to determine distinct asthma
phenotypes. Consequently, our findings challenge the paradigm in
asthma that airway wall remodeling is characterized by increased
WV but rather suggest that in asthmatic patients there is an
important component of air trapping coupled with distinct and
polarized phenotypes of proximal airway dilatation or narrowing.
Whether these changes occur in parallel to or as a consequence
of small-airways disease need to be further investigated.
Additionally, fractal analysis of the segmented airway tree and
low attenuation clusters in asthmatic patients provide a global
assessment of structural changes in airway and lung parenchyma.
The inclusion of airway structure in asthma phenotyping might
prove invaluable in patient stratification to inform underlying
mechanisms of disease and for novel pharmacologic and
nonpharmacologic treatments.
We thank our respiratory research nurses for help with patients’ clinical
characterization and colleagues in the radiology department at Glenfield
Hospital, Leicester, United Kingdom, for coordinating the CT scans.
Clinical implications: Novel asthma phenotypes based on quan-
titative CT indices were identified. This might prove useful in
patient selection for novel therapies.REFERENCES
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CT imaging of study subjects
CT acquisition. CT scans were acquired with a multidetector CT
scanner, the Siemens Sensation 16, at Glenfield Hospital, Leicester, United
Kingdom. All subjects were scanned within 30 minutes of inhalation of 2.5
mg of nebulized salbutamol in the supine position and with shoulders fully
abducted to avoid streak artifacts form arm bones. A foam box (LD15;
Styrotech Ltd, West Bromwich, United Kingdom) housing 3 electron
density rods (LN300, LN450, and ‘‘solid water’’) from an RMI467 electron
density CT phantom (Gammex-RMI Ltd, Nottingham, United Kingdom)
was secured over the midpoint on the sternum by using a Velcro belt. The
electron density rods LN300, LN450, and ‘‘solid water’’ have electron
density relative to water of 0.28, 0.40, and 0.99, respectively. Volumetric
whole-lung scans were acquired at full inspiration (near TLC) and at the end
of normal expiration (near FRC) in a caudocranial direction to minimize
motion artifacts secondary to diaphragmatic motion. All subjects rehearsed
inspiratory and expiratory breath holds at least twice before the CT scan. CT
scans were acquired with dose modulation switched off at collimation of 16
3 0.75 mm, pitch of 1.5 mm, 120 kVp, 40 mA, 0.5-second rotation time,
and scanning field of view (FOV) of 500 mm. Images were reconstructed
with a slice thickness of 0.75 mm and a slice interval of 0.5 mm by using a
low spatial frequency algorithm (B35f) through a 512 3 512 matrix, with a
field of view targeted to include pulmonary areas and a foam box containing
3 electron density rods.
CT radiation safety
Assessment of radiation exposure caused by research CT scans was
performed. The effective dose for full thoracic CT scans was calculated based
on Monte Carlo simulationsE1 of calculated x-ray spectra in an adult, her-
maphrodite, mathematic phantom by using the ImPACT CT dosimetry calcu-
lator.E2 The estimated effective dose for a full thoracic CT scan was 1.5 mSv.
The radiation dose associated with common radiologic examinationsE3 and
research CT scans is presented in Table E1.
Quantitative proximal airway and air-trapping
analysis with automated software
Fully automated software, VIDA PW2 software, was used for quantitative
airway and densitometric analysis. CT images reconstructedwith a low (B35f)
spatial frequency algorithm were used.
Three-dimensional quantitative airway analysis. The
first 5 to 6 generations of the airway tree can be segmented, labeled, and
reliably measured by using PW2 software, as described and validated
previously.E4-E7 Morphologic airway measurements were obtained along
each centerline voxel of the lumen perpendicular to the long axis on each
airway and averaged over the middle third of the airway segment. LA, total
area, and lengths of the right RB1 bronchus and other segmented airways
were measured. Average dimensions of 4 (RB1, RB10, LB112, and LB10)
segmental bronchi in asthmatic patients were also calculated. WAwas derived
from LA and total area as follows:
WA5Total area2LA:
WV, LV, and total volume were calculated by multiplying respective cross-
sectional area measurement with airway length. Percentage WV was derived
from WVand total volume as follows:
%WV5WV=Total volume3 100:
The airwaymeasurements, LA,WA, and total area were corrected for BSA.
Airway dimensions of Pi10E8 and Po20 were calculated by using regres-
sion equations based on airway dimension data for each subject. Internal
airway perimeter (Pi) was plotted against the square root of WA for all the
measured airways. The WA for a hypothetical airway with a Pi of 10 mm
was then determined. Outer airway wall perimeter (Po) was plotted against
the square root of WA and the square root of LA for all the measured airways.
The WA and LA for a hypothetical airway with a Po of 20 mm was thendetermined. Po20 percentage WA was determined from Po20 WA and Po20
LA as follows:
Po20 %WA5Po20WA=ðPo20WA1 Po20 LAÞ3 100:
Quantitative air-trapping analysis. Air-trapping quantifica-
tion was performed by using whole-lung densitometry of inspiratory (TLC)
and expiratory (FRC) CT scans with PW2 software. A threshold-based
technique is used to segment the lungs from rest of the thoracic structures and
derives densitometric indices from the voxel frequency distribution histogram.
Air-trapping indices derived were as follows:
A. VI at a threshold of 2850 HU at FRC.E9 This is defined as the propor-
tion of lung voxels of low density expressed as a percentage of less
than a threshold of 2850 HU at FRC. A CT density of 2850 HU rep-
resents the density of a fully distended alveolus. Therefore any voxels
less than 2850 HU on an expiratory CT scan must represent areas of
air trapping.
B. MLD E/I.E10
C. VI2850 change on paired inspiratory and expiratory CT scan (VI2850
E-I).E11 The percentage of lung voxels with attenuation values of less
than2850 HUwas calculated on both inspiratory and expiratory scans.
To evaluate the change in VI 2850 values, the difference between VI
2850 on expiratory CT and inspiratory CTwas calculated as follows:
VI850 E2I5VI2850 expiratory CT2VI2850 inspiratory CT:
D. Voxel index change of percentage voxels between2950 and2850 HU
on paired inspiratory and expiratory CT scans (VI2850/2950 E-I).
E11
The percentage of lung voxels with attenuation values of greater
than 2950 HU and less than 2850 HU were calculated on both inspi-
ratory and expiratory scans. On CT scans, the attenuation threshold of
2950 HU has been shown macroscopicallyE12 and microscopicallyE13
to delineate emphysematous areas of the lungs. VI-850/2950 was calcu-
lated for both inspiratory and expiratory scans by subtracting VI2950
from VI 2850. This ensures that any voxels with low attenuation
value because of emphysema are eliminated and not included in air-
trapping quantification. To evaluate the change in VI-850/2950, the dif-
ference between VI-850/2950 on expiratory CT and inspiratory CT was
calculated as follows:
VI2850=2950 E2I5VI2850=2950 expiratory CT2VI2850=2950 inspiratory CT:
The VI at a threshold of 2950 HU and 15th percentile point in HU on
inspiratory scans at TLC was also calculated to assess the degree of
emphysema, if any.E12,E13 The 15th percentile point is defined as a cutoff value
in Hounsfield units below which 15% of all lung voxels are distributed. Basic
densitometric indices are demonstrated in the line diagram (Fig E1).
All densitometric indices were standardized for extrathoracic air, blood,
and 3 electron density rods (Fig E2). Regression equations were calculated
from measurements of the densitometric standards (extrathoracic air ventral
to patient’s sternum, blood, and 3 electron density rods), with each CT scan
of every subject in relation to the standard density measures of the densito-
metric standards. The regression equations derived were used to adjust all
the densitometric indices for each CT scan of every subject. Fig E2 shows deri-
vation of the regression equation for standardization of densitometric indices
for one of the subjects.
Fractal dimension of the airway tree and low
attenuation area in lungs
Fractal dimension of the airway tree. First, the image of the
tracheobronchial tree segmented by using PW2 software was saved as a JPEG
file to perform the fractal analysis (Fig E3, A). Standard settings were used for
each image, with a size of 5133 518 pixels and resolution of 72 pixels per inch
and the subject in normal anatomic orientation. Images were first binarized by
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(black or white) for the foreground (segmented tracheobronchial tree) and
background was automatically assigned by using ImageJ software. Fractal
analysis was performedwith the morphologic image analysis software ImageJ
plug-in FracLac (version 2.5 Rel. 1e).E14,E15 The box-counting algorithm was
used to determine the fractal dimension of the binarized image of the
segmented tracheobronchial tree for each subject. This algorithm places
several grids of decreasing box size over the region of interest (ROI; ie, binar-
ized image of the tracheobronchial tree; Fig E3,C andD). The number of boxes
containing pixels with ROI detail is then counted for each grid, and data are
gathered for each box of every grid. The fractal dimension is then expressed
as the slope of the regression line for the log-log plot of box size and count.E15
The standard FracLac analyses protocol was selected in accordance with
the recommendations of the FracLac user manual.E15 The size of the series of
grids was set to decrease linearly from a maximum box size of 45% of the hor-
izontal ROI size to a minimum size of 1 pixel. Ten global scans were per-
formed for each ROI, with randomly selected starting grid locations to
improve the accuracy of the box-counting result. The following measures
were derived by using FracLac to describe the tracheobronchial branching
in asthmatic and healthy subjects:
A. Dav: The fractal dimension averaged over 10 global scans that were
done at different grid positions.
B. Dsc: As box size increases relative to image size, the number of boxes
required to cover an image stays the same over a long interval of
change in size and causes a plateau in the log-log plot of box size
and count. The slope-corrected fractal dimension is the fractal dimen-
sion corrected for periods of no change in regression data.
C. Most efficient cover fractal dimension (De): The fractal dimension
generated from box-counting data in which the box count that required
the lowest number of boxes (most efficient cover) for each grid size
was used.
D. Slope-corrected most efficient covering fractal dimension (Dsce):
Combination of Dsc and De.
Fractal dimension of low attenuation areas in lungs.
PW2 software was used to calculate the fractal dimension of the low
attenuation areas in lungs on inspiratory and expiratory scans. The low
attenuation cluster regions on CT scans are contiguous areas of voxels with CT
attenuation values of less than a given threshold. Summing the number of
voxels in a low attenuation cluster provides the cluster size. The fractal
dimension is then expressed as the slope of the regression line for the log-log
histogram plot created with low attenuation cluster size and low attenuation
cluster number.E16,E17 PW2 software calculates the fractal dimension for each
lung (right and left) separately. The fractal dimension of low attenuation areas
for each subject was expressed as an average of right and left lung fractal di-
mensions. A threshold CTattenuation value of2950 HU on inspiratory scans
and2850HUon expiratory scans was used to define low attenuation cluster to
assess the size and distribution of emphysematous lesions and air-trapping
areas, respectively (Fig E4).
Assessment of the accuracy of airway
morphometry performed using PW2 software
A phantom model, the Leicester Airway Phantom described previously,E18
consisting of a polystyrene block embedded with 9 cylindrical plastic tubes of
varying dimensions, was used. Stereomicroscopy was used to determine the
cross-sectional dimensions of the LAP tubes with an accuracy of 61 mm.
A Vernier caliper was used to measure the length of the Leicester Airway
Phantom tubes.
CT imaging of Leicester Airway Phantom was performed with Siemens
Sensation 16 scanner at Glenfield Hospital, Leicester, United Kingdom, with
scanning parameters similar to those of study subjects’ scans described above.
Images were reconstructed with a slice thickness of 0.75 mm and a slice
interval of 0.5mmby using a low (B35f) spatial frequency algorithm through a
512 3 512 matrix, with a field of view of 350 mm. Three tubes with the
smallest dimensions in the Leicester Airway Phantom were not measurable ata reconstruction FOVof 350 mm, and therefore only tubes 4 to 9 were used.
The volumetric CT scan of Leicester Airway Phantom tubes of 4 to 9 was
analyzed by using the fully automated software VIDA Pulmonary Worksta-
tion, version 2.0 (PW2, Vida Diagnostics; http://www.vidadiagnostics.
com/]. Morphologic measurements of the phantom tubes were obtained along
each centerline voxel of the lumen perpendicular to the long axis on each tube
and averaged over the middle third of the tube. LA, total area, and length of 4
to 9 phantom tubes were measured. WAwas derived from LA and total area as
follows:
WA5Total area2LA:
Repeatability analysis for LA, WA, and length measurements of Leicester
Airway Phantom tubes 4 to 9 by a single observer 2 months apart showed
excellent correlation: LA, ICC5 1 (95%CI, 0.3-1;P <.005);WA, ICC5 0.99
(95% CI, 0.3-1; P < .005); length, ICC5 1 (95% CI, 0.97-1; P < .005; 2-way
random-effects model, absolute agreement, and single-measure reliability).
Bland-Altman plots for intraobserver repeatability are shown in Fig E5. Mea-
sures of LA andWAof Leicester Airway Phantom tubes 4 to 9madewith PW2
software was compared with steromicroscope measures. Length measure-
ments of Leicester Airway Phantom tubes 4 to 9 made with PW2 software
were compared with Vernier caliper measures. No significant difference was
found when WA/LA measures made with a steromicroscope were compared
with measures obtained by using PW2 software (paired t test; mean LA,
11.9 [SD, 6.6] vs 11.1 [SD, 6.9], P 5 .06; mean WA, 21.1 [SD, 15.5] vs
20.3 [SD, 11.2], P 5 .7; Fig E6). Mean tube length was underestimated by
PW2 software compared with the Vernier caliper (paired t test; 48.1 [SD,
8.4] vs 49.4 [SD, 9.0], P 5 .01; Fig E6). Repeatability analysis for LA/WA
and length measurements of Leicester Airway Phantom tubes 4 to 9 using a
steromicroscope and Vernier caliper, respectively, compared with PW2 mea-
surements showed excellent correlation: LA, ICC 5 0.99 (95% CI, 0.82-1;
P < .005); WA, ICC 5 0.95 (95% CI, 0.7-0.99; P < .005); length,
ICC5 0.99 (95% CI, 0.52-1; P <.005; 2-way random-effects model, absolute
agreement, and single-measure reliability). Bland-Altman plots of LA and
length do not show any systematic bias. The Bland-Altman plot of WA shows
that PW2 software overestimates and underestimates dimensions of smaller
and larger tubes, respectively, compared with a steromicroscope (Fig E6).
Principal component and cluster analyses
Principal component and cluster analyses were performed by using
quantitative CT data of asthmatic patients. Healthy subjects were not included
in this analysis.
Principal component analysis. CT data were subjected to
unsupervised multivariate modeling by using principal component analysis
(orthogonal varimax rotationmethod) to extract components that best describe
the underlying relationship among the quantitative CT variables in all
asthmatic patients. Before performing principal component analysis, the
suitability of data for analysis was assessed. Inspection of the correlation
matrix revealed the presence ofmany coefficients of 0.3 or greater. TheKaiser-
Mayer-Olkin measureE19,E20 for sampling adequacy was 0.6, with the recom-
mended value being 0.6 or greater. Results on the Bartlett test of sphericityE21
reached statistical significance (P < .0005), supporting the factorability of the
correlation matrix. Independent components reflecting different asthma CT
phenotypes were identified by using principal component analysis of 11 quan-
titative CT variables that encompassed a broad range of proximal and distal
airway measures. The quantitative CT variables used for principal component
analysis were as follows: (1) RB1 LA/BSA, (2) RB1 WA/BSA, (3) RB1 total
area, (4) RB1 LV, (5) RB1 WV, (6) RB1 percentage WV, (7) expiratory VI
2850, (8) MLD E/I, (9) VI change of percentage voxels between 2950 and
2850 HU on paired inspiratory and expiratory CT scans, (10) expiratory
fractal dimension of low attenuation cluster at a threshold of 2850 HU, and
(11) inspiratory Dav of the airway tree. Before performing the principal
component and cluster analyses, all variables were Z-normalized. Analysis
identified 3 components that contributed to the data set in accordance with
the Kaiser criterionE22 (eigenvalue >1) and that accounted for 75.2% of the to-
tal population variance. Component loading for the selected variables of the 3
independent components are shown in Table E6. Component 1, which
E7. Tschirren J, Hoffman EA, McLennan G, Sonka M. Segmentation and quantitative
analysis of intrathoracic airway trees from computed tomography images. Proc
Am Thorac Soc 2005;2:484-7, 503-4.
E8. Kaminska M, Foley S, Maghni K, Storness-Bliss C, Coxson H, Ghezzo H, et al.
Airway remodeling in subjects with severe asthma with or without chronic persis-
tent airflow obstruction. J Allergy Clin Immunol 2009;124:45-51.
E9. Busacker A, Newell JD Jr, Keefe T, Hoffman EA, Granroth JC, Castro M, et al.
A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as
measured by quantitative CT analysis. Chest 2009;135:48-56.
E10. Gono H, Fujimoto K, Kawakami S, Kubo K. Evaluation of airway wall
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2003;22:965-71.
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190:762-9.
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J Respir Crit Care Med 1995;152:653-7.
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et al. Comparison of computed density and microscopic morphometry in pulmo-
nary emphysema. Am J Respir Crit Care Med 1996;154:187-92.
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GUPTA ET AL 738.e3accounted for 42.6% of total variance, correlated with RB1 LA/BSA and RB1
LV values and inversely correlated with RB1 percentage WV. Component 2
(23.3% of total variance) correlated with MLD E/I and VI change of percent-
age voxels between 2950 and -850 HU on paired inspiratory and expiratory
CT scans. Component 3 (9.3% of total variance) correlated with the expiratory
fractal dimension of the low attenuation cluster at a threshold of2850HU and
inspiratory Dav of the airway tree. The predominant variable from each
component that passed the Kaiser criterion (ie, eigenvalue >1) was selected
for statistical cluster analysis.
Cluster analysis. After identification of 3 ‘‘quantitative CT’’
components, we used cluster analysis to classify patients with asthma into
phenotypes based on quantitative CT indices. The highest loading variable
from each component (namely RB1 LA/BSA,MLDE/I, and expiratory fractal
dimension of low attenuation cluster at a threshold of2850 HU) was used for
cluster analysis. Two steps were involved in statistical cluster analysis. First,
hierarchical cluster analysis was performed with the Ward method (using
squared Euclidean distance as the interval measure), which generated a
dendrogram to determine the number of likely clusters. The period of large
change between successive fusion levels in the dendrogram were used to
define likely cluster boundaries.E23 Three clusters were estimated by using hi-
erarchical cluster analysis of the predominant variable from each component
that had been identified by using principal component analysis. Second,
k-means cluster analysis was used as the principal clustering technique,
with a prespecified number of clusters to determine the cluster membership
of asthmatic patients.E24REFERENCES
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FIG E1. Densitometric indices. A cumulative voxel distribution histogram
identifying derivation of various densitometric indices is shown. Perc15,
15th Percentile point.
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FIG E2. Standardization of densitometric indices. Regression equations were calculated from measure-
ments of the densitometric standards (extrathoracic air, blood, and 3 electron density rods) for each CT scan
of every subject in relation to the standard density measures of the densitometric standards. The regression
equations derived were used to adjust all the densitometric indices for each CT scan of every subject. The
figure illustrates derivation of regression equation for standardization of densitometric indices for one of
the subjects.
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FIG E3. Fractal analysis of the segmented airway tree with FracLac (ImageJ) software. The JPEG image (A)
of the segmented airway tree is binarized (B) by ImageJ software by assigning black pixel color for the
airway tree and white pixel color for background. The box-counting algorithm places several grids of
decreasing box size (C and D) over the ROI (ie, binarized image of the tracheobronchial tree to determine
the fractal dimension).
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FIG E4. Fractal dimension of low attenuation areas in lungs. Coronal CT image showing areas of low
attenuation less than the threshold CT attenuation value of 2950 HU on inspiratory scans (A) and 2850 HU
on expiratory scans (C), with each lobe coded with a different color. Respective low attenuation clusters are
shown in B and D, which are used to assess the size and distribution of emphysematous lesions and
air-trapping areas, respectively.
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FIG E5. Bland-Altman plots and intraobserver repeatability with PW2
software. Differences between measures of LA (A), WA (B), and length (C)
by single observers 2 months apart (y-axis) are plotted against the average
of LA (Fig E5, A), WA (Fig E5, B), and length (Fig E5, C) measurements
(x-axis).
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FIG E6. Accuracy of airway morphometry assessed by using PW2 software. Comparison of PW2 and
stereomicroscopic measures of LA (A and B), WA (C and D), and length (E and F) by using the paired t test
and Bland-Altman plots (difference [y-axis] vs the average [x-axis]measure using the 2 methods is plotted).
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FIG E7. Quantitative CT in healthy subjects and patients with severe asthma. Three-dimensional
reconstruction of an airway tree from a healthy subject (A) and a patient with severe asthma (B) using
PW2 software, illustrating that in healthy subjects subsegmental airways can be reconstructed to more gen-
erations than in asthmatic patients. This is due to increased airway narrowing and closure in asthmatic pa-
tients. The insets illustrate the cross-section of RB1 in healthy subjects and patients with severe asthma,
showing that the lumen is narrowed in asthmatic patients, with a decrease in total area and an increase
in percentage WA but a relatively preserved WA. Coronal section of expiratory CT from a healthy subject
(C) and a patient with severe asthma (D) showing the increased low attenuation areas (color coded accord-
ing to lung lobes) in patients with severe asthma compared with healthy subjects.
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FIG E8. Fractal dimension of the segmented airway tree on an inspiratory
CT scan in asthmatic patients and healthy subjects (*P < .05, ANOVA).
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TABLE E1. Radiation risk associated with common radiologic examinations in the United Kingdom compared with research CT
examinations
DLP ED Equivalent period of natural
background radiationk
Lifetime additional risk of fatal
cancer per examination{75th Percentile Mean 75th Percentile Mean
CXR (single PA radiograph)* x x x 0.02 3 d 1 in 1,000,000
Pelvic x-ray* x x x 0.7 4 mo 1 in 30,000
Barium swallow* x x x 1.5 8.5 mo 1 in 13,000
Head CT 1015 820 2.1 1.7 9.7 mo 1 in 11,700
Abdomen CT 399 312 6.0 4.7 2.1 y 1 in 10,000
Chest (cancer staging) CT 536 479 7.6 6.8 3.1 y 1 in 6,700
Full thoracic CT (research) x 93.6 x 1.5§ 8.5 mo 1 in 13,000
CTDIvol, Volume CT dose index; CXR, chest x-ray; DLP, dose-length product; ED, effective dose; PA, posterior-anterior.
*Data are based on information from the Health Protection Agency, United Kingdom.E3
Data are based on national survey of doses from CT scans in the United Kingdom in 2003.E1
Calculated from scanner CTDIvol.
§Calculated by using the ImPACT CT dosimetric calculator.E2
kAverage natural background radiation in the United Kingdom is 2.2 mSv (range, 1.5-7.5 mSv).E3
{Approximate lifetime risk for patients 16 to 69 years old: pediatric patients multiply risks by approximately 2, and older patients divide risks by approximately 5.E3
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TABLE E2. Other proximal airway dimensions
Inspiratory CT scans Patients with severe asthma
Patients with
mild-to-moderate asthma Healthy control subjects Significance (P value)
RB10 n 5 45 n 5 15 n 5 30
Wall area/BSA (mm2/m2) 17.6 (3.8) 18.2 (5.8) 19.2 (3.3) .3
Lumen area/BSA (mm2/m2) 11.8 (3.7) 12.7 (4.5) 14.0 (3.8) .05*
Total area/BSA (mm2/m2) 29.4 (7.4) 30.9 (10.2) 33.2 (6.9) .1
Wall area (mm2) 33.8 (7.1) 34.4 (10.0) 37.1 (6.3) .2
Lumen area (mm2) 22.4 (6.6) 24.0 (7.7) 27.1 (7.0) .02*
Total area (mm2) 56.3 (13.3) 58.4 (17.4) 64.2 (12.9) .06
Length (mm) 15.4 (7.2) 12.2 (4.8) 12.8 (4.8) .1
Wall volume (mm3) 504.5 (218.3) 411.4 (171.4) 465.9 (172.7) .3
LV (mm3) 332.5 (150.8) 284.5 (121.6) 334.7 (123.2) .5
Total volume (mm3) 837.0 (365.4) 696.0 (289.1) 800.6 (290.4) .4
% Wall volume 60.5 (3.1) 59.1 (2.8) 58.2 (3.4) .008*
LB112 n 5 43 n 5 15 n 5 26
Wall area/BSA (mm2/m2) 21.9 (5.4) 20.5 (4.6) 20.1 (4.4) .3
Lumen area/BSA (mm2/m2) 14.7 (6.3) 13.1 (3.6) 14.0 (4.2) .6
Total area/BSA (mm2/m2) 36.6 (11.5) 33.6 (8.0) 34.1 (8.4) .5
Wall area (mm2) 41.5 (10.4) 38.5 (7.8) 39.7 (9.3) .5
Lumen area (mm2) 27.8 (12.5) 24.5 (6.0) 27.7 (8.7) .6
Total area (mm2) 69.3 (22.5) 62.9 (13.5) 67.3 (17.8) .6
Length (mm) 10.9 (3.3) 11.3 (4.2) 12.6 (4.2) .2
Wall volume (mm3) 431.6 (110.1) 418.0 (138.6) 506.7 (242.4) .1
LV (mm3) 280.7 (86.5) 265.0 (87.9) 359.6 (202.0) .03*
Total volume (mm3) 712.3 (186.5) 683.0 (223.8) 866.3 (443.1) .07
% Wall volume 60.9 (4.3) 61.3 (2.1) 59.5 (3.0) .2
LB10 n 5 42 n 5 14 n 5 27
Wall area/BSA (mm2/m2) 19.2 (3.8) 19.6 (5.5) 20.6 (4.6) .4
Lumen area/BSA (mm2/m2) 13.0 (4.2) 12.7 (4.8) 15.9 (5.5) .03*
Total area/BSA (mm2/m2) 32.2 (7.7) 32.2 (10.1) 36.6 (9.9) .1
Wall area (mm2) 36.0 (5.9) 37.3 (9.0) 40.0 (7.9) .08
Lumen area (mm2) 24.4 (6.9) 24.1 (8.0) 30.7 (9.8) .004*
Total area (mm2) 60.4 (12.2) 61.4 (16.5) 70.8 (17.0) .02*
Length (mm) 15.5 (6.7) 15.4 (4.5) 14.1 (5.2) .6
Wall volume (mm3) 553.4 (243.1) 561.3 (192.7) 557.1 (213.0) 1.0
LV (mm3) 372.8 (181.3) 361.3 (143.0) 430.1 (209.4) .4
Total volume (mm3) 926.2 (416.7) 922.6 (331.3) 987.2 (415.4) .8
% Wall volume 60.2 (4.4) 61.2 (3.6) 57.2 (3.8) .003*
Data are expressed as means (SDs).
BSA, Body surface area.
Intergroup comparisons
One-way ANOVA with the Tukey test to compare all pairs of columns: *P < .05, patients with severe asthma versus healthy control subjects; P < .05, patients with mild-to-
moderate asthma versus healthy control subjects; and P < .05, patients with severe asthma versus patients with mild-to-moderate asthma.
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TABLE E3. Dimensions of hypothetical airways (Pi10 and Po20)
Patients with severe asthma
(n 5 48)
Patients with mild-to-moderate
asthma (n 5 17) Healthy control subjects (n 5 30) Significance (P value)
Inspiratory
Pi10 WA (mm2) 16.5 (1.7) 16.1 (1.5) 15.2 (1.3) .002*
Po20 % WA 65.2 (2.3) 64.6 (2.4) 63.4 (1.6) .002*
Data are expressed as means (SDs).
Intergroup comparisons
One-way ANOVA with the Tukey test to compare all pairs of columns: *P < .05, patients with severe asthma versus healthy control subjects; P < .05, patients with mild-to-
moderate asthma versus healthy control subjects; and P < .05, patients with severe asthma versus patients with mild-to-moderate asthma.
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TABLE E4. Fractal dimensions
Patients with severe asthma
(n 5 48)
Patients with mild-to-moderate
asthma (n 5 17)
Healthy control subjects
(n 5 30) Significance (P value)
Airway tree, inspiratory
Dav 1.688 (0.04) 1.680 (0.04) 1.718 (0.06) .007*
Dsc 1.649 (0.03) 1.637 (0.03) 1.677 (0.05) .001*
De 1.794 (0.05) 1.777 (0.04) 1.824 (0.07) .02
Dsce 1.745 (0.04) 1.731 (0.03) 1.764 (0.05) .03
Terminal airspace
Inspiratory LAC-D 2950 1.972 (0.1) 1.956 (0.1) 1.987 (0.1) .7
Expiratory LAC-D 2850 1.812 (0.1) 1.802 (0.1) 1.813 (0.1) .8
Data are expressed as means (SDs).
Intergroup comparisons
One-way ANOVA with the Tukey test to compare all pairs of columns: *P < .05, patients with severe asthma versus healthy control subjects; P < .05, patients with mild-to-
moderate asthma versus healthy control subjects; and P < .05, patients with severe asthma versus patients with mild-to-moderate asthma.
Dav, Fractal dimension, which is averaged over all 10 global scan locations; De, same as Dav but for each grid size, the box count that required the lowest number of boxes was used;
Dsc, same as Dav but corrected for periods of no change for the log-log plot of box size and count; Dsce, combination of all the above; LAC-D 2850, Fractal dimension of low
attenuation cluster at a threshold of 2850 HU; LAC-D 2950, fractal dimension of low attenuation cluster at a threshold of 2950 HU.
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TABLE E5. Univariate analysis of the relationship between proximal airway dimensions on inspiratory scans and CT air-trapping
indices (n 5 65)
Expiratory mean lung density (HU) Expiratory VI 2850 (%) MLD E/I VI2850/2950 E-I (%) VI2850 E-I (%)
RB1 LA/BSA (mm2/m2) 20.13 0.07 0.1 20.07 20.01
RB1 WA/BSA (mm2/m2) 20.07 20.02 0.11 20.09 20.01
RB1 TA/BSA (mm2/m2) 20.1 0.02 0.11 20.09 20.01
RB1 LV (mm3) 20.15 0.16 0.03 20.04 20.04
RB1 wall volume (mm3) 20.01 0.14 0.04 20.04 20.04
RB1 total volume (mm3) 20.14 0.15 0.04 20.04 20.04
RB1 % wall volume 0.14 20.2 0.002 0.04 0.03
Pi10 wall area (mm2) 20.16 0.29* 0.28* 0.40 0.35
Po20 % wall area 20.05 0.17 0.28* 0.47 0.42
Data are expressed as the Pearson correlation coefficient: *P < .05 and P < .001.
TA, Total area.
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TABLE E6. Component loading of selected variables
Components
1 2 3
RB1 LA/BSA 0.949* 0.020 0.117
RB1 LV 0.935 0.021 20.024
RB1 TA 0.905 0.050 0.231
RB1 WA/BSA 0.876 0.021 0.249
RB1 WV 0.831 0.045 0.049
RB1 % WV 20.682 0.035 0.180
MLD E/I 0.054 0.937* 20.101
VI-850/2950 E-I 20.102 0.901 0.090
Expiratory VI 2850 0.138 0.757 20.427
Expiratory LAC-D 2850 20.063 20.301 0.745*
Inspiratory Dav 0.244 0.054 0.610
Rotated component matrix
Extraction method: principal component analysis
Rotation method: Varimax with Kaiser normalization
Component loading of the 11 original variables with the 3 main components derived
by means of factor analysis in the 62 asthmatic patients is shown, with the
predominant variable in each component indicated by an asterisk.
LAC-D 2850, Fractal dimension of low attenuation cluster at a threshold of 2850
HU; TA, total area.
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TABLE E7. Asthma phenotypes (subjects with a smoking history of >10 pack years were excluded)
Asthma cluster 1: Severe air
trapping, bronchial wall thickening,
and bronchial lumen dilatation
(n 5 10)
Asthma cluster 2:
Moderate air trapping
(n 5 33)
Asthma cluster 3: Severe air
trapping and bronchial lumen
narrowing (n 5 15)
Significance
(P value)
Age (y) 52.1 (10.1) 49.2 (13.3) 54.3 (8.9) .4
Sex (M/F) 7/3 17/16 6/9 .8
Postbronchodilator FEV1 (% predicted) 61.4 (17.0) 84.2 (20.2) 72.2 (16.3) .005*
Postbronchodilator FEV1/FVC ratio (%) 65.6 (13.3) 72.8 (10.6) 68.4 (9.5) .2
Midexpiratory flow (L/s) 1.7 (1.2) 2.1 (0.9) 1.9 (0.9) .6
RV (L) 2.9 (0.8) 1.7 (0.7) 2.0 (0.9) .006*
TLC (L) 6.4 (1.4) 5.8 (1.4) 5.7 (2.1) .6
RV/TLC (%) 45.2 (11.0) 29.2 (6.5) 35.4 (9.6) <.005*
RB1 % wall volume 57.9 (2.9) 62.0 (2.6) 64.9 (2.9) <.005*
RB1 wall volume (mm3) 544.7 (96.8) 455.7 (121.3) 331.3 (107.3) <.005
RB1 wall volume (% greater than upper
95% CI of healthy control subjects)
30 15 7 .3
RB1 LV (mm3) 397.0 (81.1) 280.1 (78.2) 179.6 (56.7) <.005*
RB1 LV (% less than lower 95% CI of
healthy control subjects)
10 64 93 <.005
Expiratory VI 2850 (%) 24.9 (16.4) 17.5 (11.9) 23.4 (11.5) .2
Expiratory VI 2850 (% greater than upper
95% CI of healthy control subjects)
70 30 60 .03
MLD E/I 0.881 (0.06) 0.858 (0.06) 0.861 (0.05) .5
MLD E/I (% greater than upper 95% CI of
healthy control subjects)
80 55 67 .3
Data are expressed as means (SDs). Pearson x2 and Fisher exact tests were used to compare ratios.
FVC, Forced vital capacity.
Intergroup comparisons
One-way ANOVAwith the Tukey test to compare all pairs of columns: *P < .05, asthma cluster 1 versus asthma cluster 2; P < .05, asthma cluster 1 versus asthma cluster 3; and
P < .05, asthma cluster 2 versus asthma cluster 3.
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